Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)

NCT02089737 · clinicaltrials.gov ↗

COMPLETED

Status

3091

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Recurrent Colorectal Cancer

Interventions

DRUG: Panitumumab

Sponsor

Takeda